Alto Neuroscience has filed with the U.S. Securities and Exchange Commission to raise $129,000,000.00 in an Initial Public Offering

Alto Neuroscience has filed with the U.S. Securities and Exchange Commission to raise $129,000,000.00 in an Initial Public Offering

According to filings with the U.S. Securities and Exchange Commission, Alto Neuroscience is raising $129,000,000.00 in new funding. About Alto Neuroscience: Alto Neuroscience is redefining psychiatry by leveraging individuals neurobiology to develop personalized and highly effective medicines, helping patients get better faster. Altos Precision Psychiatry Platform measures biomarkers like EEG and wearable data, behavioral patterns, genetics, and other factors to match patients with the treatment they are most likely to respond to. Our approach matches the right patient with the right Alto drug based on AI-derived brain biomarkers, redefining psychiatry at a time when the world needs it most.

To learn more about Alto Neuroscience, visit http://www.altoneuroscience.com/

Contact:
Amit Etkin, Chief Executive Officer
650-200-0412
https://www.linkedin.com/in/amit-etkin/

SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.

Comments are closed.